Friday 12 July 2019 12:37 am

City Moves for 12 July – Who’s switching jobs at Healx, Ergomed and Olim?


Send your appointments to citymoves@cityam.com

Send your appointments to citymoves@cityam.com

Today’s City Moves includes Healx, Ergomed and Olim.

Healx

Healx, a Cambridge-based biotechnology company working on breakthrough treatments for rare diseases, has appointed Dr Neil Thompson as chief scientific officer (CSO). Neil, who will spearhead the expansion of Healx’s drug discovery and development team, brings more than 30 years of experience in the biotech and pharmaceutical industries. He previously was senior vice president of biology at another Cambridge-based company, Astex Pharmaceuticals, for 15 years. Since leaving Astex in 2017, Neil has been working as a consultant. His earlier career included working for multinational pharmaceutical company Glaxosmithkline as director of immunology platform. Healx was founded in 2014 by Dr Tim Guilliams, founder of the Cambridge Rare Disease Network, and Dr David Brown, the co-inventor of Viagra and ex-global head of drug discovery at Roche.

Ergomed

Ergomed, a company focused on providing specialised services to the pharmaceutical industry, has announced its intention to appoint Dr Jim Esinhart as a non-executive director. Jim is widely recognised as a leading figure in the global contract research and pharmaceutical industry. He began his career in industry at Glaxosmithkline specialising in infectious disease research. He went on to co-found Pharmaresearch, one of the first specialised clinical trial outsourcing companies focused on respiratory, oncology and infectious diseases, in 1995. In eight years, the company grew to more than 420 employees worldwide and was sold to Inveresk Research in 2003. After a period at Inveresk and Charles River Laboratories, Jim joined Chiltern International in 2006 and became chief executive in 2012. His tenure culminated in Chiltern’s sale to Covance, a division of US-listed healthcare company Laboratory Corporation of America (Labcorp) in 2017.

Olim

Olim Investment Managers has appointed Henry Botting as assistant investment manager. Henry joins from Rathbones Investment Management, where he began his career in 2014 as assistant investment manager for a desk managing £1bn on behalf of private clients, trusts and charities. A CFA charterholder, Henry will assist with managing both equity and balanced portfolios at Olim, which has managed equity portfolios for charities, private clients and retail investors since 1987 and is a subsidiary of independent investment manager Albion Capital. Olim director Andrew Impey described Henry as “an exciting talent in our sector.”

Main image credit: Getty

Share